52266-53-2

Usage

Type of compound

Salt form of 1-(2-Pyridyl) piperazine

Use

Ligand in the synthesis of coordination complexes and coordination polymers

Application

Research and pharmaceutical settings as a reagent for the preparation of biologically active molecules and as a precursor for the synthesis of other organic compounds

Advantage

Dihydrochloride form allows for easy handling and storage

Potential applications

Medicinal chemistry and drug development due to its ability to modulate biological processes and interact with various targets in the body

InChI:InChI=1/C9H13N3.2ClH/c1-2-4-11-9(3-1)12-7-5-10-6-8-12;;/h1-4,10H,5-8H2;2*1H

Upstream product

• 504-29-0 2-aminopyridine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 77278-62-7 tert-butyl 4-(pyridin-2-yl)piperazine-1-carboxylate 

Downstream Products

• 462995-90-0 1-(4-fluorophenyl)-2-(4-pyridin-2-ylpiperazin-1-yl)ethanone 
• 107778-36-9 1-phenyl-3-(4-pyridin-2-yl-piperazin-1-yl)-propan-1-one 
• 94029-86-4 1-phenyl-3-(4-pyridin-2-yl-piperazin-1-yl)-propan-1-ol 
• 154558-38-0 1-(2-(bis(4-flurophenyl)methoxy)ethyl)-4-(pyridine-2-yl)piperazine 
• 1357455-85-6 C₂₉H₃₆N₄O₂S 

Relevant academic research and scientific papers

Highly Selective Sub-Nanomolar Cathepsin S Inhibitors by Merging Fragment Binders with Nitrile Inhibitors

Pharmacological inhibition of cathepsin S (CatS) allows for a specific modulation of the adaptive immune system and many major diseases. Here, we used NMR fragment screening and crystal structure-aided merging to synthesize novel, highly selective CatS inhibitors with picomolar enzymatic Ki values and nanomolar functional activity in human Raji cells. Noncovalent fragment hits revealed binding hotspots, while the covalent inhibitor structure-activity relationship enabled efficient potency optimization.

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

Exploration of substituted arylpiperazine–tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors

In the search for potent dual norepinephrine and dopamine reuptake inhibitors, several substituted arylpiperazine–tetrazoles were designed, synthesized and evaluated for their neurotransmitter reuptake inhibitory activities. Various derivatives exhibited selective and strong neurotransmitter reuptake inhibitory activity. In particular, compounds with a three-carbon linker displayed selective and stronger potency than those with two-carbon and four-carbon linkers. Interestingly, six compounds, 9b, 9c, 9d, 9o, 9q and 9u displayed more effective activity than the standard drug, bupropion. The provided SAR data and potent biological activity can offer useful guidelines for designing dual norepinephrine and dopamine reuptake inhibitors as effective therapeutic agents for treatment of several central nervous system diseases.

THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION

Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. The compounds and compositions can be used to modulate an isocitrate dehydrogenase (IDH) mutant (e.g., IDHIm or IDH2m) having alpha hydroxyl neoactivity

Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation

A compound having the formula (I) or a pharmaceutically acceptable salt thereof: STR1 wherein all the symbols are defined in the specification; having valuable pharmaceutical properties, useful for the treatment of mental disorders, such as psychoses, dep